



Is Perioperative Immunotherapy the New Standard of Care?

Rachel E. Sanborn, M.D.

Medical Director, Thoracic Oncology Program Medical Director, Phase I Clinical Trials Program Earle A. Chiles Research Institute, Providence Cancer Institute November 22, 2024





What is the Gold Standard for Clinical Trial Outcomes? --Overall Survival--


What is the Main Goal Desired by Patients With NSCLC?

--The treatment that helps them live longest--

Randomized Phase III Trials, Resectable NSCLC

NCE


	Perioperative Treatment?	EFS HR	OS HR			
CM 816	No	0.63	?			
KN-671	Y	0.59	0.72			
CM 77T	Y	0.58	?			
AEGEAN	Y	0.68	?			
RATIONALE-315	Y	0.56	0.62 (Interim Analysis)			



	-	-			- 1	50	50	1-	10	51		
Number at risk	Time since randomisation (months)											
(number censored)												
Pembrolizumab group	397	371	347	327	277	205	148	108	69	32	4	0
	(0)	(1)	(1)	(4)	(38)	(95)	(145)	(182)	(218)	(255)	(283)	(287)
Placebo group	400	379	347	319	256	176	125	77	39	20	4	0
	(0)	(2)	(4)	(5)	(45)	(106)	(147)	(190)	(219)	(236)	(252)	(256)

Spicer J et al, Lancet 2024





An OS benefit trend (HR=0.62 [95% CI: 0.39, 0.98]; one-sided P=0.0193) was observed favouring perioperative TIS

OS was defined as the time from the date of randomisation to the date of death due to any cause. Abbreviations: CI, confidence interval; HR, hazard ratio; ITT, intention-to-treat; NE, not evaluable; NR, not reached; OS, overall survival; PBO, placebo; TIS, tislelizumab.

Dongsheng Yue

Content of this presentation is copyright and responsibility of the author. Permission is required for re-use.

Yue D et al, ESMO 2024






Questions From the Data

- Are the results definitely due to perioperative treatment?
 - Unknown
- Are the results specific to the immunotherapy (or chemotherapy) agent?
 - (Probably not)
- Are there specific subgroups that benefit more/less?
 Most likely






Median follow-up (range): 25.4 months (15.7-44.2).

Cascone T et al, ASCO 2024

EARLE A. CHILES RESEARCH INSTITUTE CAncer Institute CM 77T, Evaluation BY N2 Disease

CheckMate 77T: clinical outcomes with perioperative NIVO by nodal status

Landmark EFS from definitive surgery



Median follow-up (range): 25.4 months (15.7-44.2). aN2 subcategory was not reported in 1 patient in the NIVO arm.

Cascone T et al, ASCO 2024



CM 77T, Evaluation by pCR




Stage III non-N2

PROVIDENCE

Cancer Institute

Landmark EFS from definitive surgery by pCR status

Stage III N2



Landmark EFS HRs for no pCR^a: 0.59^b (single-station N2) and 0.36^c (multi-station N2)^d

Median follow-up (range): 25.4 months (15.7-44.2). aHRs were NC for patients with pCR as there were < 10 patients in either treatment arm. b,c95% CI: b0.29-1.20; c0.12-1.09. aN2 subcategory was not reported in 1 patient in the NIVO arm.

Cascone T et al, ASCO 2024





Questions From the Data

- Do the results prove benefit of perioperative treatment?
 - No, but intriguing evidence

- Does this give information to select who gets adjuvant immunotherapy?
 - Not yet




50 2024 World Conference on Lung Cancer

SEPTEMBER 7-10, 2024 | SAN DIEGO, CA USA




Perioperative vs neoadjuvant nivolumab for resectable NSCLC: patient-level data analysis of CheckMate 77T vs CheckMate 816

Patrick M. Forde,¹ Solange Peters,² Jessica Donington,³ Stephanie Meadows-Shropshire,⁴ Phuong Tran,⁴ Stefano Lucherini,⁵ Cinthya Coronado Erdmann,⁶ Hong Sun,⁶ Tina Cascone⁷






Landmark EFS (BICR) from definitive surgery





• HR (95% CI): ATT^d weighted analysis, 0.56 (0.35-0.90); unweighted analysis, 0.59 (0.38-0.92)



Landmark EFS^a (analysis population) by pCR status^{a,b}











Questions From the Data

- Do the results prove benefit of perioperative treatment?
 - No, but strong evidence
- Does this give information to select who gets adjuvant immunotherapy?
 - Not yet
- Are there patient populations more tempting for adjuvant immunotherapy?

- Yes

- Can we definitely select who should NOT receive adjuvant immunotherapy?
 - Not yet





How Do We Decide?

- Patients with pCR?
 - Less benefit with adjuvant?
- Patients with PD-L1 negative?
 - Benefit with adjuvant
- Patient with Stage II (Benefit), without pCR (Benefit), PD-L1 positive (No Benefit)?

All hypothesis-generating but not ready for clinic tomorrow



Head to head comparative studies

Including different populations (pCR vs no, etc)

• Novel perioperative combination trials





What Treatment Schedule Has Been Shown to Help Patients Live the Longest? Perioperative Immunotherapy Is the New Standard of Care

